Tirabrutinib

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

15 evidence topics · 7 sources

Systemic chemotherapy2 evidence topics · 2 sources
Anti-CD20 monoclonal antibodies1 evidence topic · 1 source
High-dose chemotherapy with autologous stem cell transplantation1 evidence topic · 1 source
Radiotherapy1 evidence topic · 1 source
Bruton tyrosine kinase inhibitors2 evidence topics · 2 sources
Immunomodulatory agents1 evidence topic · 1 source
Intrathecal and intravitreal chemotherapy2 evidence topics · 2 sources
Immune checkpoint inhibitors1 evidence topic · 1 source
CAR t-cell therapy1 evidence topic · 1 source
Corticosteroids and supportive care1 evidence topic · 1 source
Limitations of current therapies2 evidence topics · 2 sources